glp 1 thyroid cancer risk of medullary with GLP-1 receptor agonist use for more than year may increase GLP-1 Receptor Agonists and Thyroid – Do GLP-1s cause thyroid cancer?

Researchers recruited 338 adults who had a BMI over 30 or a BMI of 2730 with one or more weight-related conditions and were assigned to one of the following experimental groups or a placebo group: 1 mg of subcutaneous retatrutide 4 mg of subcutaneous retatrutide, starting at an initial dose of 2 mg 4 mg of subcutaneous retatrutide, starting at an initial dose of 4 mg 8 mg of subcutaneous retatrutide, starting at an initial dose of 2 mg 8 mg of subcutaneous retatrutide, starting at an initial dose of 4 mg 12 mg of subcutaneous retatrutide, starting at an initial dose of 2 mg The trials promising results pave the way for further phase 3 research to evaluate retatrutides efficacy in comprehensive obesity management and its impact on associated health issues

53 HuiY.WangD.LiW.ZhangL.JinJ.MaN.et al (2011)

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates the secretion of growth hormone (GH) by mimicking the natural ghrelin hormone

-